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Abstract It is generally recognized that a large fraction of the
humanproteome ismadeupof proteins that remaindisordered
in their native states. Despite the fact that such proteins play
key biological roles and are involved in many major human
diseases, they still represent challenging targets for drug dis-
covery. A major bottleneck for the identification of
compounds capable of interacting with these proteins and
modulating their disease-promoting behaviour is the devel-
opment of effective techniques to probe such interactions. The
difficulties in carrying out binding measurements have
resulted in a poor understanding of the mechanisms underly-
ing these interactions. In order to facilitate further
methodological advances, herewe review themost commonly
used techniques to probe three types of interactions involving
small molecules: (1) those that disrupt functional interactions
between disordered proteins; (2) those that inhibit the aberrant
aggregation of disordered proteins, and (3) those that lead to
binding disordered proteins in their monomeric states. In
discussing these techniques, we also point out directions for
future developments.
Keywords Disordered proteins  Small molecules 
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Introduction
Disordered proteins do not adopt well-defined secondary
and tertiary structures under native conditions [1–7]. These
proteins can be represented as ensembles of many
conformationally distinct states, each with its own statis-
tical weight (i.e. its probability of being occupied) [1–7].
Quite generally, all proteins exhibit some level of disorder,
ranging from those that have just short dynamic terminal
regions to those that are almost completely unstructured
[1–7]. In many cases, the conformational heterogeneity of
the latter proteins is believed to play important biological
roles, as it enables them to interact with myriad partners.
This multifunctionality is further enhanced by structural
variations from post-translational modifications, as well as
by the presence of multiple isoforms as a result of alter-
native splicing or pre-translational modifications [8].
Consequently, disordered proteins and proteins with dis-
ordered regions can act as central hubs in protein
interaction networks for crucial regulation and signalling
processes [9, 10]. Thus, it is not surprising that the dys-
regulation of disordered proteins is often correlated with
biochemical pathways involved in cancer, cardiovascular
diseases, diabetes, autoimmune disorders, and neurode-
generative conditions [10–12]. Illustrative examples of the
involvement of disordered proteins in disease include the
Cip/Kip cell cycle inhibitors, breast cancer type 1 suscep-
tibility protein, and securin in the case of cancer, amyloid
b, tau, a-synuclein, and huntingtin in the case of neu-
rodegenerative disorders, and amylin (IAPP) in the case of
type II diabetes [13].
For both structured and disordered proteins, the molec-
ular mechanisms underlying protein-associated diseases
can be divided into two broad categories, as a pathological
condition can be triggered by either the total or partial
inactivation of a protein (loss of function) or the acquisition
of a new aberrant activity (gain of function). A well-known
example of loss-of-function mechanism involving a disor-
dered protein is that of the tumour suppressor protein, p53.
p53 is a multi-domain protein with extended unfolded
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regions under native conditions, including its N-terminal
and C-terminal domains. Several cancer-related mutations
of p53 are localized in these regions and alter the inter-
actome of this protein, thereby inhibiting its regulatory
activity [8, 14]. On the other hand, an example of a dis-
ordered protein that exhibits gain of toxic function in
disease is a-synuclein. Several missense mutations and
genomic multiplications of a-synuclein affect its native
state, solubility and cellular interactions, eventually
prompting the protein to form amyloid aggregates associ-
ated with Parkinson’s disease [15–22].
Despite the high prevalence of disordered proteins in
diseases, it is still very challenging to target these proteins
using therapeutic compounds [11, 12, 23–29]. Two major
obstacles in the drug discovery process for disordered
proteins are: (1) the limited number of fully quantitative
experimental techniques that can accurately probe disor-
dered protein interactions with candidate therapeutic
molecules compared to those available for ordered pro-
teins, and (2) a lack of understanding of the molecular
mechanisms underlying such interactions.
For the past six decades, techniques such as X-ray
crystallography have yielded highly accurate structural
insights about ordered proteins, which have paved the way
for drug discovery and potency-optimization efforts. Such
techniques, however, are generally poorly informative in
the case of disordered proteins as a result of their highly
dynamical nature. Progress has been made when the dis-
ordered proteins are not fully disordered and have highly
ordered regions or domains for which crystal structures can
be obtained, as was done to identify small-molecule inhi-
bitors of the cancer-associated p53-murine double minute 2
(MDM2) interaction [30, 31]. However, protein crystal-
lization is largely inapplicable to the vast majority of
disordered proteins due to their conformational hetero-
geneity. While ordered proteins usually have a single, well-
defined conformation representing a global free-energy
minimum with the potential to bind small molecules with
high affinity, the free-energy landscape of disordered pro-
teins is characterized by a large number of local minima
(Fig. 1). These minima correspond to the many confor-
mations within the structural ensemble populated by
disordered proteins, which can transiently bind small
molecules with very weak affinity. In fact, disordered
proteins can remain disordered in their bound states, and
characterization of these bound states is only recently
becoming possible due to experimental and computational
advances [32–35]. There are also examples of disordered
proteins interacting with partner proteins in which they
undergo disorder-to-order transitions through coupled
folding upon binding mechanisms [36, 37] or templated-
folding [38], resulting in high specificity, but low affinity
complexes with usually large surface areas [37]. While
these folded complexes may be crystallized, the identifi-
cation of potential binding pockets from the crystal
structures of the bound states is far from trivial [23].
Despite these challenges, several small molecules have
been identified to modulate the behaviour of disordered
proteins including the neurodegeneration-associated a-
synuclein [39] and amyloid b [40], and the cancer-associ-
ated p27Kip1 [41], c-Myc [35, 42–44], and EWS–FLI1 [45].
To make further progress, effective techniques to probe
small-molecule binding to disordered proteins must be fur-
ther developed. Indeed, the lack of such methods has been a
major bottleneck for the identification of molecules able to
interact with disordered proteins and modulate their disease-
promoting behaviour. The current situation has resulted in a
poor understanding of the mechanisms underlying these
interactions, which has, in turn, hindered the development of
drugs active against disordered proteins. In this review, we
highlight themost prominent techniques that have enabled so
far major contributions to be made to the understanding of
whether and how small molecules can alter the disease-
promoting behaviour of disordered proteins.
Methods of identifying inhibitors of interactions
between disordered proteins
The lack of well-structured binding sites within disordered
proteins makes it challenging to target them directly using
well-established drug discovery techniques developed for
Fig. 1 Schematic representation of the free-energy landscapes of
ordered and disordered proteins. Structured or ordered proteins (red)
have a free-energy landscape with a well-defined global minimal
conformation, which can bind small molecules with high affinity. In
contrast, disordered proteins have multiple minima within their free-
energy landscape, which represent the many conformations capable of
interacting with small molecules with lower affinities
G. T. Heller et al.
123
ordered proteins such as enzymes and receptors. Instead,
some approaches involve targeting disordered proteins
indirectly, by blocking their binding interfaces with other
proteins [46] and lipid membranes [47]. In the cases where
the binding surfaces are structured and well characterized,
this approach can be highly specific, as it may be amenable
to standard affinity-optimization techniques. However, a
thorough understanding of the binding partners involved,
as well as the contact sites of interest, must usually already
be well established. In this section, we discuss the state of
art of this approach and present some notable examples of
what we define here as ‘interface blockers’.
Perhapsone of themostwell studied systems in this context
is the interaction between the two disordered proteins, c-Myc
and Max, which have been probed by a wide variety of
techniques. c-Myc is a transcription factor associated with
many types of cancer, whose interaction with its regulator
Max is associatedwith cellular growth,metabolism, apoptosis
and differentiation [48, 49]. A basic helix–loop–helix-leucine
zipper (bHLHZip) in each of these two proteins facilitates
their coupled folding and binding upon dimerization, creating
an interface of approximately 3200 A˚2 in the coiled-coil
dimer [35, 43, 46, 50]. The identification and characterization
of small-molecule inhibitors of this interaction has repre-
sented a major milestone in demonstrating the feasibility of
therapeutic targeting of disordered proteins.
Fluorescence resonance energy transfer
Inhibitors of the c-Myc/Max association were found via
high-throughput screening assays of combinatorial small-
molecule or peptidomimetic libraries based on fluorescence
resonance energy transfer (FRET, Table 1) measurements
of the bHLHZip domains of c-Myc and Max fused to cyan
fluorescent protein (CFP) and yellow fluorescent protein
(YFP), respectively [51–53].
FRET signals arise upon the interaction of two chro-
mophores, whereby an excited donor chromophore
transfers its excitation energy to a nearby acceptor chro-
mophore through nonradiative dipole–dipole coupling.
This transfer of energy results in both a quenching of the
fluorescence of the donor and an appearance of a fluores-
cence emission spectra of the acceptor. Importantly, the
efficiency of the energy transfer is strongly dependent on
the distance between the donor and acceptor (in the range
between 1 and 10 nm), thereby enabling FRET to effec-
tively quantify molecular associations [54].
In a seminal study, c-Myc/Max FRET experiments
identified two compounds, called IIA4B20 and IIA6B17,
capable of inhibiting c-Myc-dependent cell growth [51].
These molecules, however, also showed activity against
another oncogenic transcription factor, c-Jun, suggesting
poor specificity. Nevertheless, a follow-up study using a
related combinatorial library with members assembled
from a racemic, trans-3,4 dicarboxylic acid template yiel-
ded c-Myc/Max dimerization inhibitors that did not affect
c-Jun [52], suggesting that specificity is potentially
achievable in targeting disordered proteins.
Additional libraries have been screened against c-Myc/
Max interfaces based on FRET experiments. One library
consisted of 285 so-called ‘credit card’ compounds,
designed to insert themselves into a shallow protein–pro-
tein interface hotspot of about 600 A˚2 rich in hydrophobic
and aromatic residues, and force the protein partners to
remain in their monomeric forms [53]. After FRET
screening, the initial hits were further characterized by an
electrophoretic mobility shift assay (EMSA) to confirm
their activity. Based on the observation that the elec-
trophoretic mobility of a bound system is less than that of
the unbound system, EMSA provides quantitative infor-
mation about modifiers of DNA-binding protein complexes
[55]. In general, compounds in the ‘credit card’ library tend
to be planar, with varying chemical diversity, designed to
have favourable enthalpic contributions from van der
Waals interactions, p-stacking, and favourable entropy
gains from desolvation [53]. Two compounds, NY2267 and
NY2280, were identified to disrupt c-Myc–Max dimeriza-
tion, and inhibit both specific DNA binding and its
associated oncogenic transformation. As in the case of
IIA4B20 and IIA6B17, however, these molecules also
showed an inhibition of c-Jun [53].
FRET experiments have also been used to characterize
the conformational changes induced when the natural
product trodusquemine (also known as MSI-1436)
allosterically inhibits protein-tyrosine phosphatase 1B
(PTP1B) by interacting with its disordered region. By
labelling the N- and C-termini of PTP1B with CFP and
YFP, respectively, conformational changes upon binding
could be detected, suggesting that the presence of tro-
dusquemine induced a more compact structure upon
binding [56]. This binding-induced conformational change
was further characterized by nuclear magnetic resonance
(NMR) spectroscopy and small-angle X-ray scattering
(SAXS), discussed in the ‘‘Methods of characterizing
ligand interactions with monomeric disordered proteins’’.
Yeast two-hybrid system
Another powerful high-throughput screening technique
involves using a yeast two-hybrid system to identify small
molecules capable of disrupting protein-protein interaction.
In a yeast two-hybrid system (Table 1), two candidate
interacting proteins are fused to the DNA-binding domain
(BD) and the activation domain (AD) of a transcription
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factor, which hence functions only when a complex
between the two proteins is formed. Using this setup the
HLHZip domains of c-Myc and Max were fused to the BD
and AD domains, respectively, of the yeast transcription
factor Gal4. Only upon c-Myc/Max dimerization a fully
functional transcriptional activator is produced, which is
able to induce the expression of b-galactosidase from the
corresponding gene containing a Gal4-binding site within
its promoter [44] (Fig. 2). As small molecules that alter this
association prevent the induction of b-galactosidase in a
quantitative manner, yeast two-hybrid systems represent
effective screening tools to identify interface blockers. We
Table 1 Summary of techniques discussed in this review
Technique Applicability Limitations Throughput Selected
examples
Further
reading
Fluorescence
resonance
energy transfer
(FRET)
Detection of modulators of
protein–protein interactions;
detection of protein–ligand
interactions
Fluorescent labels
required
High c-Myc/Max and ligands
[51–53], protein-
tyrosine phosphatase
1B and MSI-1436 [56]
[54]
Yeast two-hybrid
system
Detection of modulators of
protein–protein interactions
Indirectly quantitative High c-Myc/Max and ligands
[44, 58]
[200]
Fluorescence
polarization
Detection of modulators of
protein–protein interactions;
detection of protein–ligand
interactions
Fluorescent labels
required
High c-Myc/Max and ligands
[43], c-Myc-Max
complex/DNA and
ligands [59, 60]
[61–63]
Circular
dichroism
spectroscopy
(CD)
Determination of the changes in
secondary structure upon
binding
Low sensitivity Low c-Myc/Max and ligands
[35, 43]
[65, 201]
Fluorescence-
based
aggregation
kinetic assays
Identification of inhibitors of
protein aggregation
Fluorescent dyes
required
High Ab [40], a-synuclein [47] [89, 92, 97]
Surface-plasmon
resonance/other
surface-based
techniques
Real-time detection of
modulators of protein–protein/
interactions; detection of
protein–ligand interactions
Non-specific interactions
may yield false
positives
Medium EWS-FLI1 and
YK-4-279 [45]
[116, 117, 202]
Small-angle X-ray
scattering
(SAXS)
Detection of large
conformational changes upon
binding at nanometer
resolution
Low resolution Variable Protein-tyrosine
phosphatase 1B and
trodusquemine [56]
[114, 115]
Thermal
denaturation
screening
Detection of monomeric binders Non-quantitative High Nuclear protein 1 and
ligands [119]
[203]
Isothermal
titration
calorimetry
(ITC)
Label-free measurement of the
heat associated with binding
events
Significant heat change
required upon binding
Medium–
low
Nuclear protein 1 and
ligands [119]
[121]
Single-molecule
techniques
Determination of the structure
and dynamics of disordered
proteins in presence of ligands
Labels required Medium–
low
a-Synuclein [125, 129] [125]
Mass
spectrometry
Localization of noncovalent
interactions
May miss ligand
interactions, gas-phase
dissociation constants
may differ from solution
Low Polycationic spermine
and a-synuclein [141]
[133, 134, 204]
Nuclear magnetic
resonance
(NMR)
spectroscopy
Detection of protein–ligand
interactions at atomic
resolution
Ligand monitoring: fast,
protein monitoring:
time intensive, isotopic
labelling may be required
Medium–
low
Osteopontin/heparin
[169], protein-tyrosine
phosphatase 1B and
trodusquemine [56]
[145, 147]
Integrative
structural
biology
methods
Modelling of unbound/bound
structural ensembles
Time intensive,
computationally
expensive
Low c-Myc and ligands
[28, 34]
[6]
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should add, however, that although high-throughput
screening approaches of this type identified a number of
c-Myc/Max dimerization inhibitors, screening against other
similar dimers suggested that the majority of the resulting
hits lacked specificity. Many of these hits, including the
small molecule 10058-F4, were confirmed to directly
interact with monomeric HLHZip region of c-Myc
[35, 43]. The optimization of the 10058-F4 structure led to
analogues with increased potency [42], and the develop-
ment of a pharmacophore model [57]. A further discussion
of the interaction of 10058-F4 with its c-Myc is continued
below in the ‘‘Methods of characterizing ligand interac-
tions with monomeric disordered proteins’’. A yeast two-
hybrid system was also used to identify dihydroxycapnel-
lene, a coral-derived sesquiterpene capable of preventing
c-Myc–/Max dimerization and effective against the pro-
liferation of cancer cells [58].
Fluorescence polarization
Further studies focused on targeting the interface between
the c-Myc/Max dimer and DNA by screening molecular
Fig. 2 Schematic representation of the yeast two-hybrid system. In
the type of yeast two-hybrid system used to identify inhibitors of
c-Myc/Max dimerization [51–53], recombinant genes encoding the
HLHZip domain of c-Myc fused to the DNA-binding domain and
HLHZip domain of Max fused to the transcriptional activation
domain are introduced into a yeast cell (a). Upon c-Myc/Max
association, the transcriptional activation domain induces expression
of b-galactosidase in a quantitative manner (b)
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libraries based on fluorescence polarization experiments
[59, 60] (Table 1). Fluorescence polarization is a physical
phenomenon that occurs when fluorescent small molecules
are excited with polarized light. The resulting emitted light
is largely depolarized due to the rapid tumbling of the
small molecules in solution. However, when the small
molecules are bound to other species, this tumbling is
quantitatively slowed as their effective hydrodynamic radii
are increased, thereby better maintaining the polarization
of the emitted light (Fig. 3). Because the measured polar-
ization value is a weighted average of the free and bound
states, fluorescence polarization is an important biophysical
tool for drug discovery to measure the fraction of a fluo-
rescent ligand bound to a receptor [61–63].
Fluorescence polarization screens identified two com-
pounds, Mycro1 and Mycro2, capable of preventing DNA
binding of the c-Myc/Max dimer and transcription, mea-
sured by a c-Myc reporter gene. This approach was
implemented by labelling the DNA target sequences with
fluorophores. However, these molecules showed signs of
non-specificity as they also inhibited Max/Max DNA
binding in addition to transcription from an AP-1 depen-
dent reporter [59]. Upon further screening of Mycro1 and
Mycro2 derivatives, Mycro3 was identified to strongly
inhibit c-Myc transcription while leaving AP-1 unaffected
[60]. Furthermore, once the binding sites of 10058-F4, as
well as that of the compound 10074-G5, within the c-Myc
monomer were established using deletion and mutagenesis
studies of the bHLHZip domain of c-Myc, fluorescence
polarization competition affinity experiments were per-
formed to determine the binding sites of seven other
inhibitors, taking advantage of the intrinsic fluorescence of
the drug-like molecules. Six of these seven compounds
bound one of the binding sites already established, whereas
one, 10074-A4, bound a region adjacent to the site of
10075-G5. It is notable that these three binding sites are all
within a span of 85 residues, which suggests that drug-
binding regions may fall within specific disordered
sequences [43].
Circular dichroism spectroscopy
The case of targeting monomeric c-Myc demonstrated the
feasibility of targeting a disordered protein in its mono-
meric state as a therapeutic strategy [25, 35, 44, 64]. Many
different optical techniques contributed to the
Fig. 3 Schematic representation of a fluorescence polarization
experiment. As a result of rapid tumbling of molecules in solution,
when a fluorescently labelled ligand is excited with plane-polarized
light, the resulting emitted light is largely depolarized (a). Upon
binding another species, a larger proportion of the emitted light
remains in the same plane as the excitation energy, because the
rotation is slowed as the effective molecular size increases, whether it
is an ordered molecular structure (b) or one that is disordered (c)
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characterization of this type of binding interaction,
including in particular circular dichroism (CD) experi-
ments (Table 1), which are based on the differential
absorption of left- and right-handed circularly polarized
light and can be used to determine the secondary-structure
content of proteins. With this approach it was demonstrated
that 10058-F4 and 10074-G5 caused an unfolding of the
c-Myc/Max coiled-coil dimer into disordered monomeric
states. Furthermore, CD was used to confirm the two dis-
tinct 11 and 19-residue binding regions identified for
10058-F4 and 10074-G5, respectively, by deletion and
mutagenesis studies. This binding was further character-
ized by performing fluorescence polarization titrations,
which take advantage of the intrinsic fluorescence of these
compounds [35, 43]. In addition to conventional CD
experiments, CD spectroscopy obtained using beamline
synchrotron radiation offers improved sensitivity at a wider
range of wavelengths to detect subtle changes upon com-
plex formation [65].
Byproducts of screenings to identify enzyme
inhibitors
Small molecules have also been identified to interact with
the Alzheimer’s-related disordered amyloid-b peptide (Ab,
discussed more in detail below). Serendipitously, some of
these small molecules were not identified by direct
screening against the peptide itself, but rather during a
search for modulators of c-secretase, which, together with
b-secretase, cleaves the amyloid precursor protein (APP) to
produce toxic Ab. Derivatives of two modulators (taren-
flurbil and fenofibrate) were created to contain a
benzophenone group (a UV-active moiety used for label-
ling) and a biotin tag. It was thus found that these
derivatives bind directly to APP within the Ab region, and
act as a ‘molecular clamps’ or substrate-targeted inhibitors
preventing the cleavage of Ab [66].
Chemical kinetics approaches to identify protein
aggregation inhibitors
Under certain conditions, some disordered peptides and
proteins, such as Ab, a-synuclein and amylin, undergo a
self-assembly process, which leads to the formation of
fibrillar aggregates known as amyloid fibrils. This aggre-
gation process is typically associated with pathological
conditions such as Alzheimer’s and Parkinson’s diseases,
and type II diabetes [15, 67–69]. Given the clinical rele-
vance of the aggregation phenomenon, efforts have been
put forward to inhibit the aggregation process from
occurring, many of which have been carried out via in vitro
assays [23, 70–77].
The kinetics of formation of these aggregates can be
monitored experimentally via the use of amyloid-specific
fluorescent dyes (Table 1), such as the thioflavin T (ThT).
Complementary biophysical techniques to monitor this
process include transmission electron microscopy (TEM),
atomic force microscopy (AFM), and Fourier transform
infrared spectroscopy (FTIR). Such experiments highlight
the presence of three typical macroscopic phases of
aggregation in vitro, namely, the lag phase, growth phase,
and plateau phase. The molecular pathways that control
this aggregation process, however, have been extremely
difficult to characterize, mainly because of the challenges
in establishing accurate and highly reproducible in vitro
assays for monitoring fibril formation and in formulating
an overall kinetic theory to analyse the resulting mea-
surements. For example, as the aggregation of Ab has
emerged as a key feature of the onset and progression of
Alzheimer’s disease [78, 79], various compounds [80–87]
have been reported to interfere with the aggregation pro-
cess of Ab, but none of these molecules has yet found a
therapeutic application because of the poor understanding
of their mechanism of action.
Recently, this situation has begun to change due to
advances in defining a chemical kinetics theory of aggre-
gation [15, 88, 89]. It is now understood that the overall
aggregation process is the result of complex non-linear
combinations of microscopic events, including: (1) primary
nucleation, in which initial aggregates form from mono-
meric species; (2) elongation, in which existing fibrils
increase in length by monomer addition, (3) secondary
nucleation, whereby the surfaces of existing aggregates
catalyse the formation of new aggregates and (4) frag-
mentation in which existing fibrils break apart, increasing
the total number of fibrils [15, 88]. The contributions of
each of these microscopic events to the lag, growth, and
plateau phases are highly protein and condition specific. It
has thus become possible to obtain microscopic rates from
macroscopic measurements, thereby revealing the mecha-
nisms of aggregation of specific proteins and the effects of
small molecules on such mechanisms [15, 88, 89].
Furthermore, reproducible protocols to measure the
kinetics of Ab aggregation have also been established
[88, 90–92], thus providing accurate data that could be
fitted with the chemical kinetics theory. These advances
have helped in elucidate the crucial mechanisms in the
aggregation process of Ab42, the 42-residue form of Ab,
which forms the most toxic species associated with Alz-
heimer’s disease. In particular, it has been found that once
a critical concentration of amyloid fibrils has formed,
secondary nucleation overtakes primary nucleation in
becoming the major source of toxic oligomers [93]. Further
developments of this chemical kinetics framework have
shown that therapeutic strategies against amyloid
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aggregation should not simply aim at a complete inhibition
of fibril formation, but rather at specifically targeting toxic
oligomeric species, as generic and non-specific effects
could lead to the increase in the concentration of these
oligomers and hence result in a negative outcome in terms
of suppressing pathogenicity [89].
Recently, the small molecule bexarotene was discovered
to target the primary nucleation step in the aggregation of
Ab42. Its presence delays the formation of oligomers of
Ab42 and suppresses the toxicity in neuroblastoma cells
and in a Caenorhabditis elegans model of Ab-mediated
dysfunction. While this small molecule suggests that
compounds may be found that act as ’neurostatins’ to delay
Alzheimer’s disease if taken before the onset of disease,
research efforts are now also focused on developing a
strategy for specifically targeting secondary nucleation
processes which may yield a therapeutic capable of
inhibiting toxicity after the onset of symptoms [40]. As a
proof-of-principle, it has been demonstrated that the
molecular chaperone Brichos is able to block the formation
of toxic oligomers of Ab42 by specifically inhibiting the
secondary nucleation [94, 95]. To this end, kinetic analysis
applied to a range of derivatives of bexarotene has been
recently employed in order to evolve systematically
potential inhibitors and to obtain libraries of compounds
with increased anti-aggregation activity [96] (Fig. 4).
In contrast to monitoring aggregation with fibril-specific
dyes, an alternative in cell high-throughput screening
method for detecting Ab inhibitors has been proposed
which involves the expression of a fusion of Ab42 to the
green fluorescent protein (GFP) in Escherichia coli cells. In
the absence of inhibition, the aggregation of Ab42 results
in a quenching of the GFP fluorescence. However, in the
presence of an aggregation inhibitor, the fluorescence of
GFP is preserved, thus enabling the identification of
molecules based on a triazine scaffold that inhibit Ab
aggregation [97].
Furthermore, in addition to small-molecule compounds,
protein-like compounds capable of specifically suppressing
protein aggregation have inspired new technological
advances aimed to produce peptides, such as b-hairpins
[98] and b-breakers [99, 100], antibodies [101], antibody
fragments [102, 103], or other biomolecules, including
molecular chaperones [104], to act as highly effective and
specific protein aggregation inhibitors. Specifically, anti-
body fragments, particularly single-domain and single-
chain antibodies, are becoming highly explored molecules
for the inhibition of amyloid aggregation. Since the first
production of conformationally distinct antibodies able to
uniquely target fibrillar and oligomeric species of various
amyloidogenic proteins [105], many other amyloid-specific
antibodies have been generated by means of direct immu-
nization or using hybridoma technology [101], phage
display [106] or, more recently by rational design
[99, 103].
In addition to directly modulating homogeneous aggre-
gation processes, as illustrated above in the case of
bexarotene for Ab aggregation, small molecules have also
been shown to also impact heterogeneous nucleation pro-
cesses associated with aggregation. For example, the
antimicrobial aminosterol, squalamine, alters the hetero-
geneous aggregation of a-synuclein [47]. The primary
nucleation of a-synuclein is an intrinsically slow process,
whose rate increases by a thousand fold as a consequence
of the interaction of a-synuclein monomers with lipid
membranes [107]. Squalamine has been proved to inhibit
Fig. 4 Schematic representation of a fluorescence-based kinetic
aggregation assay. Aggregation assays to monitor the kinetics of
formation of fibrillar aggregates are performed using a fluorescence
dye molecule, in this case thioflavin T (ThT). Binding can be fitted
with a kinetic model from which microscopic aggregation parameters
can be derived [88, 91, 92]. Monitoring how these microscopic
parameters change in the presence of small molecules is a powerful
approach for screening molecules capable of inhibiting the aggrega-
tion process [40, 89]
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the lipid-induced primary nucleation of a-synuclein by
displacing monomers from the membranes [47].
In summary, as the cases of the Ab and a-synuclein
have shown, reproducibility of high-throughput fluores-
cence aggregation assays and a chemical kinetic
framework underlying these complex aggregation pro-
cesses have emerged as essential tools to identify
molecules as modulators of these toxic aggregation pro-
cesses. Furthermore, these tools enable the quantification
of the effects of such therapeutics on various microscopic
aggregation steps, thus creating novel opportunities in drug
discovery against neurodegenerative diseases.
Methods of characterizing ligand interactions
with monomeric disordered proteins
Experimental methods to characterize the binding
of molecules to disordered proteins in their
monomeric forms
In contrast to targeting disordered proteins in their aggre-
gated or bound forms, it is often desirable to target them in
their monomeric forms, upstream of any biological effect.
Small molecule binding to a monomeric disordered protein,
however, may come at a high entropic cost due to
restraining a conformationally heterogeneous protein into a
bound state [11]. Consequently, disordered protein inter-
actions with small molecules are not readily amenable to
the traditional ‘binding site docking’, which is generally
exploited in the case of designing and optimizing small-
molecule binders of structured proteins. Even some
mechanisms used to describe protein–protein interactions
involving at least one disordered partner tend to not be
applicable because generally in these cases, since the
enthalpic contributions over large interaction surface areas
outweigh the entropic costs. In the case of small molecules,
which lack these large surface areas, the entropic cost of
restraining a disordered protein can be too high. Instead,
the currently reported interactions between small mole-
cules and monomeric disordered proteins are relatively
weaker than traditional drug–protein interactions [2], may
involve multiple binding sites, and the protein may remain
disordered in its bound state [108].
X-ray crystallography is the gold standard for deter-
mining small-molecule binding sites within ordered
proteins for which an average conformation is well defined
at the atomic level by mapping corresponding electron
densities to atomic coordinates [109]. In the case of dis-
ordered proteins, however, dynamical regions generally
appear as missing electron density [110–113]. Therefore,
solution-state techniques that do not require crystallization,
such as nuclear magnetic resonance (NMR) spectroscopy
and other techniques described here (Table 1), coupled
within integrative structural biology methods (Table 1) are
better suited to probe disordered proteins, as they can
directly characterize their conformational heterogeneity.
Small-angle X-ray scattering
Small-angle X-ray scattering (SAXS, Table 1) is a label-free
biophysical technique that is particularly well suited to
quantitatively analyse heterogeneous and flexible systems
such as disordered proteins in solution [114]. Based on the
scattering of X-rays upon exposure to a sample, it is a useful
technique to quantify conformational changes upon ligand
binding [115]. As previously mentioned, SAXS, in combi-
nation with FRET and NMR experiments, was employed to
demonstrate the compaction of PTP1B upon binding tro-
dusquemine, which alters the allosteric communication of the
disordered C-terminal region of PTP1B and the folded cat-
alytic domain, thereby inhibiting its phosphatase activity [56].
Surface plasmon resonance and other surface-based
techniques
Surface plasmon resonance (SPR, Table 1) is a sensitive,
label-free, optical method based on the detection of the
Fig. 5 Schematic representation of mass spectrometry with electron
capture dissociation (ECD). This is a technique that enables the
identification of local binding regions within disordered proteins.
ECD breaks covalent backbone bonds of the disordered protein, while
leaving noncovalent interactions intact, thus preserving the disordered
protein–ligand interaction [141]
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changes upon binding of the refractive index at the surface
of a bio-functionalized gold-coated prism. At certain angles
of incidence, electrons at the gold surface absorb some
photons of the incident light, giving rise to surface plas-
mons. Because this phenomenon is extremely sensitive to
changes in the surface of the biochip due to changes in
mass, SPR is particularly sensitive for monitoring associ-
ation and dissociation of biomolecules immobilized on a
surface. SPR was used to screen a 3000-molecule library
for small molecules able to bind EWS–FLI1, a predomi-
nantly disordered oncogenic fusion protein associated with
Ewing’s sarcoma family tumours [45]. An initial hit was
optimized to produce the small molecule YK-4-279, with a
reported affinity of 10 lM, which showed in vitro and
in vivo inhibition of the RNA helicase A binding ability of
EWS–FLI1. Like SPR, other surface-based techniques
including bio-layer interferometry (BLI) [116] and quartz
crystal microbalance (QCM) [117] are extremely sensitive
and well suited to study disordered protein interactions
with small molecules [25]. We also point out, however,
that with any surface-based technique, one should carefully
minimize any non-specific interaction with the sensor or
the tip, or to account for them appropriately in the analysis
[118].
Thermal denaturation screening
By comparing temperature-dependent denaturation patterns
of proteins in the presence and absence of small molecules,
one can identify potential hits, because interacting ligands
may induce structural rearrangements and changes in sta-
bility (Table 1). These effects can also be monitored
extrinsically using dyes, such as 8-anilino-1-naphthalene
sulfonic acid (ANS), whose fluorescence increases upon
binding to hydrophobic protein regions. This screening
method was recently exploited to identify several binders,
including trifluoperazine, of nuclear protein 1 (NUPR1)
[119], which is of great therapeutic interest due to its
association with pancreatic adenocarcinoma, and many
other diseases [120]. However, one shortcoming of this
approach is that there is no direct correlation between the
stabilization effect and the affinity, making it difficult to
rank hits.
Isothermal titration calorimetry
Isothermal titration calorimetry (ITC, Table 1) is an
experimental technique that measures the heat exchanged
during binding events between molecules in solution [121].
In this experiment, direct measurements of the absorbed or
released heat are taken as one binding partner (either the
protein or ligand) is titrated into a solution containing the
second binding partner, offering invaluable information
that cannot be readily observed by other means. In one
single experiment, one can obtain the binding constant
(Kd), Gibbs free energy of binding (DG), enthalpy (DH),
entropy (DS), and stoichiometry of the interaction. Fur-
thermore, ITC has many advantages over other techniques;
measurements can be carried out in a physiologically rel-
evant buffer, no surface effects need to be taken into
account, and the species of interest do not need to be
immobilized or labelled [121]. In a standard setup, one
binding partner, whose concentration is known, is titrated
into a solution of the second binding partner, whose con-
centration is also known, while changes in the heat of the
system are monitored. Over time, the protein–ligand sys-
tem reaches equilibrium while the differences between heat
changes diminish. Plotting the heats of the titration as a
function of the molar ratio of ligand and protein inside the
cell yields a curve that can be analysed with a binding
model to determine the thermodynamic parameters [121].
In the case of disordered proteins, ITC can be particu-
larly useful when a protein adopts a rigid conformation
upon binding a partner, such that the contributions of
enthalpy to the Gibbs free energy are significant. Such
contributions can arise from the formation and breaking of
noncovalent bonds, namely protein-solvent hydrogen
bonds, protein–ligand bonds, van der Waals interactions,
salt bridges, reorganization of atoms and solvent molecules
near the binding site, and many more. ITC enabled a val-
idation and quantitative ranking of the binders of NURP1
(introduced above in the ‘‘Thermal denaturation screen-
ing’’) in terms of affinity, and suggested that this binding is
largely entropically driven [119].
Single-molecule methods
Major technological advances have recently created
exciting opportunities to probe disordered protein interac-
tions with ligands at the single-molecule level. Single-
molecule techniques (Table 1) are particularly promising
to probe the structure and function of disordered proteins,
because measurements are not ensemble-averaged as in the
case of the vast majority of other available experimental
techniques. Generally, two types of these experiments can
be performed to elucidate the interactions of disordered
proteins with binding partners: fluorescence-based tech-
niques [122, 123] and force-probe methods [124].
Single-molecule FRET measurements are one of the
several fluorescence experiments that can be performed at
the single-molecule level. Similarly to the bulk-phase
FRET experiments (described above), single-molecule
FRET techniques require labelling with donor and acceptor
dyes, but both the dyes are generally on the same protein.
Experiments can either be performed on surface-immobi-
lized samples using a total internal reflection fluorescence
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(TIRF) setup or performed on freely diffusing molecules.
While TIRF may enable the collection of long measure-
ments of the fluctuations of a single molecule, interactions
with the surface can perturb the native ensemble of the
disordered protein. Consequently, it is more common to
perform experiments on freely diffusing disordered pro-
teins in which a laser is focused at a dilute solution (usually
50–100 pM) of labelled protein. The resulting fluorescence
from both the donor and acceptor is measured and related
to the distance between the two fluorophores, thereby
reflecting the conformation of that molecule in the presence
or absence of a ligand. Unlike bulk FRET measurements,
this value is not ensemble-averaged, and many measure-
ments enable one to construct the distribution of
conformations within a given sample [125]. For example,
single-molecule FRET was applied to study the confor-
mations and dynamics of monomeric a-synuclein in the
presence of sodium dodecyl sulphate (SDS) as a lipid
mimetic. This technique enabled a detailed thermodynamic
characterization of the multi-state conformational changes
of a-synuclein folding in the presence of SDS [126].
Single-molecule force-probe microscopy also offers
intriguing complementary approaches to the single-mole-
cule fluorescence-based methods. These techniques involve
the use of optical tweezers, magnetic tweezers, or atomic
force microscopy by which the ends of individual protein
molecules are constrained in order to apply and measure
forces which yield information about their extensions and
resulting conformational transitions [127]. This type of
approach has been widely employed for characterizing the
conformational and dynamic behaviour of disordered pro-
teins, including a-synuclein [128, 129] and Ab [130].
Furthermore, these techniques have characterized disordered
and unfolded proteins in the presence of binding partners,
including molecular chaperones [131] and ions [132].
Mass spectrometry methods
The development of soft ionization methods, such as
electrospray ionization (ESI) and matrix-assisted laser
desorption/ionization (MALDI), has facilitated the appli-
cation of mass spectrometry (MS) to protein
characterization and protein binding, offering insight on
stoichiometry, reversibility, specificity, and binding
affinities [133, 134]. Furthermore, MS is a particularly
powerful probe of protein behaviour due to its ability to
monitor discrete conformers in a mixture [135–137]. While
there are a number of MS-based techniques to probe pro-
tein behaviour, ranging from those that monitor how
variance in buffer conditions affect the distribution of
charge states into the gas phase [138, 139], to those that
trap protein ions in the gas phase and observe conforma-
tional changes on a ls–s timescale [140], here we highlight
one particular advance that has enabled the localization of
a ligand binding site within a disordered protein. By
combining ESI-MS with electron capture dissociation
(EDC), a technique to fragment gas-phase ions (Fig. 5), the
polycationic compound spermine was found to bind a-
synuclein in the region of residues 106–138. It was shown
that EDC breaks certain covalent backbone bonds of a-
synuclein, while leaving noncovalent interactions intact,
thus preserving the spermine–a-synuclein interaction
[141]. This technique is highly complementary to nuclear
magnetic resonance spectroscopy (see below) and other
biophysical measurements, although it should be noted that
the parameters observed in the gas phase may differ from
those in solution, as the hydrophobic effect is essentially
lost in the gas phase, while electrostatic interactions are
strengthened due to the fact that the dielectric constant is
lower than water [142, 143]. We also mention that MS
methods have been applied to identify inhibitors of
aggregation (introduced above) [134, 144].
Nuclear magnetic resonance spectroscopy
Nuclear magnetic resonance spectroscopy (NMR, Table 1)
can be employed in two complementary ways to monitor
the binding between a disordered protein and a small
molecule. Changes in the one-dimensional hydrogen
spectrum of the ligand in the presence of a disordered
protein offer a fast and sensitive indication of binding, but
offers little insight regarding the binding site and mode of
interaction. In addition, monitoring the protein (which
usually requires 15N or 13C isotopic labelling) is a powerful
method that can yield informative structural and dynamical
binding information about disordered proteins, as a result
of a systematic series of advances within the past decade
[145–148]. In particular, the sensitivity of the latter tech-
nique offers highly quantitative insights into how the
properties of disordered proteins change in the presence of
small molecules. Quite generally, in NMR structural
information is derived by exploiting the conformational
dependence of the transitions between different energy
levels of atomic nuclear spins, which can be made to split
in an external magnetic field and resonate using electro-
magnetic radiation. While, in contrast with structured
proteins, nuclear Overhauser effects (NOEs) [148] cannot
always be readily exploited to obtain inter-proton distances
for disordered proteins due to their conformational
heterogeneity, other NMR parameters, including chemical
shifts, hydrogen exchange rates, residual dipolar couplings
(RDCs) and paramagnetic relaxation enhancements
(PREs), can provide atomic-resolution structural informa-
tion [145, 147, 149–151].
In contrast to the high-resolution assignments for glob-
ular proteins, which can be obtained using triple resonance
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coherence transfer experiments on isotopically labelled
proteins, equivalent measurements of disordered proteins
often yield overlapping peaks within collapsed spectra.
This is a result of a combination of structural disorder and
solvent exposure, which creates similar environments for
many residues. This problem is often worsened by the low
sequence complexity found within disordered proteins
[145, 147, 152, 153], especially as they are enriched in
proline residues, which are invisible to hydrogen-detected
NMR spectra [154, 155]. Furthermore, such high solvent
exposure also contributes to decreasing the signal-to-noise
ratios for disordered proteins, as significant chemical
exchange with bulk solvent reduces the intensities of amide
hydrogen signals. While signal overlap of disordered pro-
teins can be partially ameliorated by sample preparation at
low pH and by taking measurements at low temperatures,
the largest improvements have been a result of techno-
logical advances. Such advances include increased
instrumental sensitivity, faster sampling rates exploiting
longitudinal relaxation enhancements [156] and the use of
non-uniform sampling for high-dimensionality experiments
[145, 152, 153, 157, 158]. Additionally, by replacing
hydrogen detection with carbon detection and by exploiting
cryoprobe technology, it is possible to separate peaks
accurately, while remaining insensitive to broadening and
salt concentrations [147, 152, 153, 159]. Despite their poor
spectral resolution, disordered proteins produce particu-
larly sharp peaks, making them ideal for relaxation
experiments, and as such, additional improvements include
relaxation-optimized detection schemes [145, 160]. Fur-
thermore, the structural properties of the aggregates formed
by some disordered proteins can be studied by other NMR
techniques such as solid-state magic-angle spinning which
is discussed in detail elsewhere [161, 162].
Among the most useful NMR parameters for charac-
terizing disordered proteins that we discuss here are
chemical shifts, which report on the population-weighted
average across the conformations sampled within a mil-
lisecond time scale. By calculating deviations from random
coil values, one can describe the local geometry and
quantify local secondary structure propensity in disordered
proteins [163–165] and quantify changes in the absence
and presence of therapeutic molecules. Furthermore, 2D
NMR ‘fingerprint’ spectra, most commonly obtained with
either 1H detected 1H–15N (HN) [166] and 13C detected
13C0–15N (CON) [167] for disordered proteins, are simple
indicators of monomeric binding, and provide highly
detailed site-specific information if protein assignments
have already been established. While the HN experiment
has higher sensitivity and requires less time to record, the
CON experiment displays better spectral resolution, can
detect proline residues, and is not prone to hydrogen-ex-
change-induced line broadening, and thus spectra can be
recorded at higher pH and temperatures [159]. Chemical
shift perturbations are a sensitive technique that can
simultaneously provide binding affinity (Kd) values and
insight about a binding site or the location of conforma-
tional changes induced upon binding (Fig. 6). Finally,
within integrative methods (see below), chemical shifts can
be used to determine structural ensembles of disordered
proteins [168].
Two-dimensional (2D) 1H–15N heteronuclear single
quantum coherence spectroscopy (HSQC) experiments
were used to confirm the binding of heparin to the intrin-
sically disordered osteopontin [169], an extracellular
structural protein associated with many pathological con-
ditions, including autoimmune diseases [170], cancer
metastasis [171], Crohn’s disease and ulcerative colitis
[172], allergy and asthma [173], and muscle disease [174].
Chemical shift differences only at certain residues between
the free and bound forms of osteopontin suggested a
specific interaction, and enabled mapping of the binding
site [169]. Similarly, 2D 1H–15N HSQC experiments were
used to characterize the specific binding of hits from
‘fragment-like’ small-molecule hits against p27, a disor-
dered cell cycle regulator protein. These hits were
identified from 1D 1H WaterLOGSY [175] and standard
transfer difference (STD) [176] NMR screening methods,
and one molecule in particular, was shown to inhibit the
Cdk2/cyclin A binding function of p27 by fluorescence
anisotropy and 2D 1H–15N TROSY [41]. A similar
Fig. 6 Schematic illustration of the chemical shift perturbation
mapping method. By identifying and quantifying changes in two-
dimensional spectra (in this case 1H–15N HSQC) in the absence (red)
and presence (blue) of ligands, chemical shift perturbation mapping is
a powerful technique to identify whether ligands interact with
disordered proteins, and identify binding sites or locations of
conformational change
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approach based on 2D 1H-15N TROSY [160] measure-
ments was used to characterize the binding site of
trodusquemine to the disordered C-terminal region of
PTP1B [56]. Modifications to the HN and CON spectra
enable the detection of other observables including RDCs,
PREs, cross-relaxation and cross-correlation rates, in
addition to solvent exchange rates. All these observables
describe the structure and dynamics of disordered proteins
at atomic resolution and are sensitive to changes in the
presence of small molecules.
As mentioned above, RDCs are additional sensitive
NMR observables that are particularly well suited to study
disordered proteins in their monomeric states. These
observables arise when disordered protein samples are
partially aligned in a magnetic field by preparing samples
in anisotropic media, for example, in a liquid crystal [177],
polyacrylamide gels [178], filamentous phages [179], or
bicelles [180]. As a result of restricted overall reorientation
in the presence of the anisotropic media and dynamic
conformational averaging, non-zero RDCs are observed
which reflect the weighted average conformation of the
ensemble [180]. Additionally, chemically modifying the
disordered protein of interest with covalently attached
paramagnetic spin labels, one can observe PREs, which
report on tertiary structure, and the distances and orienta-
tions with respect to the principal axes frame of the
Fig. 7 Schematic
representation of integrative
methods for protein ensemble
generation. Integrative (or
hybrid) methods, such as
metainference [191, 199],
combine the strengths of
experimental techniques and
computational methods to
overcome the challenges
associated with each technique
alone [6]
Fig. 8 Summary of approaches for modulating the behaviour of
disordered proteins using small molecules. Small molecules can be
used to: a disrupt functional interactions, b modify the properties of
native states, or c inhibit aberrant aggregation. Modifying the
properties of monomeric disordered proteins (b) has the potential to
also inhibit (a, c)
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paramagnetic centre. As for chemical shifts, RDCs and
PREs can be implemented as structural restraints for
ensemble generation [181], which is discussed in the next
section.
Integrative methods to characterize the effects
of small molecules on protein ensembles
It is becoming increasingly clear that disordered proteins
often bind ligands in transient and delocalized manners, in
which the disordered protein remains in a disordered state
upon association [32–34, 108]. In this context, high-reso-
lution characterizations of conformational ensembles of
disordered proteins, and of the ways in which such
ensembles change in the presence of therapeutic molecules,
have the potential to yield both functional mechanistic
details and insights towards drug optimization.
Unfortunately, however, such detailed descriptions are
currently difficult to obtain because the dynamic nature of
disordered proteins makes it challenging to acquire accu-
rate experimental measurements, as well as to interpret
them in terms of structural models [5]. For example, as
noted above, while NMR spectroscopy and other solution-
state methods can provide valuable information on struc-
tural ensembles, these techniques alone are insufficient to
provide all the conformational restraints needed to fully
characterize the conformations within such ensembles.
This is because experimental techniques, in addition to
being inevitably affected by systematic and random errors,
often measure sparse and sometimes ambiguous time- and
ensemble-averages over the many heterogeneous confor-
mations of the disordered proteins [6, 182].
To overcome these problems, computational techniques
such as molecular dynamics simulations can provide
accurate descriptions of protein ensembles [6]. In these
simulations, the conformational space of a protein is
sampled via the integration of the equations of motion over
a sufficiently long time interval to ensure the exploration of
the most relevant states and corresponding estimates of
their populations. Such approaches have been used to
investigate many small-molecule interactions with disor-
dered proteins, particularly amyloidogenic ones
[41, 83, 183–185] in addition to identifying potential
binding pockets within disordered monomers [186].
Unfortunately, however, despite continuous advances, the
force fields used to represent the interatomic forces needed
to solve the equations of motion are still approximate
[187–189], which leads to the need of validating the results
through the comparison with experimental data [184, 186].
We should also remark that as most proteins of interest
are large macromolecules in a complex environment, they
are at the limit of what can be simulated. Conformational
sampling as a result of limited computational resources is
in fact often a major issue. While this problem can be
partially alleviated through the use of enhanced sampling
techniques [190, 191], the resulting ensembles may still be
dependent on the simulation time, which is an approxi-
mation that requires careful control.
We believe that an effective way forward is to bring
together the advantages of the experimental and compu-
tational approaches (Fig. 7). A series of recent results
indicate that by combining sparse experimental data on
disordered proteins with a priori information from force
fields [192–195] in molecular dynamics simulations, it is
possible to generate descriptions of conformational
ensembles with corresponding equilibrium probabilities for
each state, such that the ensembles are consistent with the
overall theoretical understanding of disordered proteins
and with the available experimental data. There are many
available methods for integrative structural ensemble
determination of heterogeneous systems [6]. Because of the
limited space that we have here, however, we only briefly
highlight recent advances which enable one both to
incorporate experimental data directly as structural
restraints and to account for systematic and random errors
by employing Bayesian inference techniques. These
include ‘multi-state Bayesian modelling [196, 197], the
‘Bayesian ensemble refinement [198], and ‘metadynamic
metainference’ [191, 199].
Integrative structural biology methods were used to char-
acterize the binding interactions between binding sites within
c-Myc and small molecules.Metadynamics simulations using
NMR chemical shift data [35] as restraints were employed to
show that these interactions are highly delocalized, the bind-
ing sites remain disordered, and the conformational space of
the binding regions are slightly altered [28, 34].
In summary, integrative computational methods for
determining ensembles of disordered proteins that incor-
porate experimental measurements and account for
different sources of error represent a powerfully detailed
and increasingly accurate approach to study the behaviour
of ensembles in the presence of candidate therapeutic
molecules.
Conclusions and outlook
We have discussed three strategies to use small molecules
to modify the behaviour of disordered proteins (Fig. 8). We
have begun with the strategy of modulating the functional
interactions involving disordered proteins using small-
molecule inhibitors. We then reviewed recent advances in
using chemical kinetics to identify compounds capable of
blocking the aggregation of disordered proteins, and finally
discussed methods of finding small molecules capable of
binding disordered proteins, emphasizing the importance of
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more closely integrating experimental and computational
techniques. Overall, we believe that upon further devel-
opments, the methods that we have reviewed will lead to a
progressive ability to identify compounds of therapeutic
interest for disordered proteins. We anticipate that an area
of research of crucial importance will be to understand the
role of specificity in these interactions, which will likely
require the development of new assays, as well as possibly
innovative conceptual tools.
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